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Purpose 
Visceral Leishmaniasis (VL) is the second deadliest parasitic disease after malaria managed mainly by parenteral 
chemotherapeutics. Buparvaquone (BPQ), a hydroxylnaphtoquinone with known antileishmaniasis activity (ED50:0.05μM), 
has not been translated into an effective therapy due to its low aqueous solubility (<30ngmL-1, BCS Class II). The current 
project is aimed at enhancing the solubilisation capacity and oral bioavailability of BPQ in the gut by encapsulation in self-
nanoemulsifying drug delivery systems (SNEDDS) prepared from GRAS excipients towards the development of an oral, 
thermally stable and ideally solid nanomedicine for the treatment of VL. 
Methods 
Pseudoternary phase diagrams were constructed to optimize BPQ-SNEDDS (BS) (Capryol:Labrafil M1944:Labrasol:BPQ 
3:1:5.99:0.01w/w/w/w). BPQ loading was quantified after centrifugation of BS containing excess BPQ (RP–HPLC). Stability 
studies of BS were performed at 40±2oC and 75±5% relative humidity. BPQ solid SNEDDS (BSS) were prepared by 
adsorption of BS on acid-degraded glycol chitosan (14 kDa) and mixing with lactose and croscarmellose sodium prior to 
lyophilisation and characterisation (PXRD, DSC, FT-IR, TEM, SEM). BS filled capsules and BSS compressed tablets 
underwent dissolution testing. The in vitro anti-leishmanial activity against L. infantum  promastigotes was assessed. RP-
HPLC was used to analyse plasma levels achieved after oral administration of BS or BPQ. 
Results 
The maximum loading of BPQ in SNEDDS was 16.92±1.59mgg-1. BS aqueous dispersions elicited quasispherical 
nanoparticles (241±49.6nm) (Figure 1A) that remained stable over 10 weeks (content, size and ζ-potential). The porous BSS 
elicited similar size nanoparticles upon reconstitution. Near complete release was observed with BS capsules and BSS tablets 
(Figure 1C,D). BS and BSS possess potent in vitro efficacy (nanomolar range) with negligible cytotoxicity. Hydrogen 
bonding between the hydroxyls of glycol chitosan and the quinine carbonyl group of BPQ was indicated (Figure 1G,F). BS 
significantly enhanced the bioavailability of BPQ after oral administration (55% increase in plasma AUC0-24). 
Conclusion 
Developed SNEDDS or solid-SNEDDS prepared from GRAS excipients are cost-effective, stable oral alternatives for the 
delivery of poorly soluble antiparasitic drugs.
  
 
